 |
|
|
| |
Peginterferon Lambda-1a (Lambda) is Associated With Less Autoimmune Thyroid Disease
and Serious Autoimmune Disease Than Peginterferon Alfa-2a (Alfa) When Used in Combination With Ribavirin (RBV) for the Treatment of Chronic Hepatitis C Virus Infection
|
| |
| |
Reported by Jules Levin
APASL Liver Week 2013: The 2013 Annual Meeting of the Asian Pacific Association for the Study of the Liver. Singapore, June 6-10, 2013
Peginterferon Lambda: new interferon in phase 3 now
EASL 2012: Peginterferon Lambda-1A (Lambda) Compared With Peginterferon Alfa-2A (Alfa) in Treatment- Naive Patients With HCV Genotypes 2 or 3: First SVR24 Results From EMERGE Phase IIb - (04/20/12)
APASL 2012: PEGINTERFERON LAMBDA-1a(LAMBDA) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGINTERFERON ALFA-2a(ALFA-2a) IN PATIENTS WITH CHRONIC HCV INFECTION (G1/2/3/4): EMERGE PHASE 2bTHROUGH WEEK 12RESULTS - (02/27/12)
APASL 2012: SAFETY AND EFFICACY OF PEGINTERFERON LAMBDA-1a (LAMBDA) COMPARED WITH PEGINTERFERON ALFA-2a (ALFA-2a) IN HCV-INFECTED PATIENTS (G1/2/3) WITH COMPENSATED CIRRHOSIS: EMERGE PHASE 2b EFFICACY AND SAFETY RESULTS THROUGH WEEK 12 - (02/27/12)
Fredlund P,1 Hillson J,2 Gray T,2 Shemanski L,2 Dimitrova D,3 Lopez-Talavera JC4
1Consultant to Zymogenetics, Bristol-Myers Squibb, Seattle, WA; 2Zymogenetics, Bristol-Myers Squibb, Seattle, WA;
3Global Pharmacovigilence and Epidemiology, Bristol-Myers Squibb, Hopewell, NJ; 4Research and Development, Bristol-Myers Squibb, Wallingford, CT
|
| |
|
|
|
|
|
